Genmab (GMAB)
Biotech
Close on Nov 12, 2026 (from our latest Long View update): $51.74
- Market value
- $31.8Bat the Nov 12 close
- Revenue growth
- +19%FY2025 (20-F)
- FCF margin
- 30%FY2025 (20-F)
- Net debt
- $3.6Bat Dec 31, 2025
- Worst fall since listing
- −84.2%Jun 2, 2009 to Aug 8, 2011; back to that high in Sep 2013
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
The Long View
For most of its history Genmab has lived on royalties from drugs it discovered and licensed out, chiefly Darzalex.
▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash
Updated Nov 12, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
More of our coverage that names Genmab
Long-term fundamentals
Annual results for Genmab, FY2021–FY2025, as reported in its 20-F annual reports.
Revenue and free cash flow
Revenue went from $1.3B in FY2021 to $3.7B in FY2025.
Free cash flow was positive in 5 of the 5 years shown; FY2025: $1.1B.
Margins
Operating margin was 29% in FY2025, vs 35% in FY2021.
Gross margin was 94% in FY2025, vs 100% in FY2021.
Diluted share count
The diluted share count fell 5% from FY2023 to FY2025, to 63M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $3.7B | 94% | 29% | $963M | $1.2B | $55M | $1.1B |
| FY2024 | $3.1B | 95% | 31% | $1.1B | $1.1B | $44M | $1.1B |
| FY2023 | $2.4B | 99% | 32% | $631M | $1.1B | $54M | $1.0B |
| FY2022 | $2.0B | 100% | 43% | $750M | $555M | $45M | $510M |
| FY2021 | $1.3B | 100% | 35% | $470M | $354M | $40M | $314M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 63M | $1.7B | $5.3B | $128M | — | $430M |
| FY2024 | 65M | $3.0B | $0 | $105M | — | $560M |
| FY2023 | 66M | $4.2B | $0 | $85M | — | $81M |
| FY2022 | — | $3.2B | $0 | — | — | — |
| FY2021 | — | $3.1B | $0 | — | — | — |
Source: company 20-F annual reports via SEC EDGAR (XBRL data); fiscal years. Data fetched Oct 30, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 20-F data.
- Genmab files annual reports on Form 20-F (IFRS). US dollars have been its presentation currency since Jan 1, 2025; FY2021–FY2025 come from the 2025 annual report's key figures (Exhibit 15.3 to the 20-F), which restate earlier years in US dollars. Years before 2021 (Danish kroner) are not shown, so the series stays in one currency. Cash includes marketable securities. Capital spending includes investments in intangible assets, as in Genmab's own key figures. Under IFRS, interest paid is in operating cash flow and lease payments are financing cash flows, so free cash flow here does not deduct lease payments. One American depositary share (ADS) represents one-tenth of an ordinary share.
- Gross profit is revenue minus cost of revenue (the 20-F does not report a gross profit line).
- Reviewed figures: Genmab 2025 annual report, Key Figures (USD millions), Exhibit 15.3 to the 20-F filed Feb 17, 2026.
Returns by year
| Year | GMAB | S&P 500 |
|---|---|---|
| 2019 | +35.5% | +31.5% |
| 2020 | +82.1% | +18.4% |
| 2021 | −2.7% | +28.7% |
| 2022 | +7.1% | −18.1% |
| 2023 | −24.9% | +26.3% |
| 2024 | −34.4% | +25.0% |
| 2025 | +47.6% | +17.9% |
| 2026 to date | +66.7% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- ALNY Alnylam
- MRNA Moderna Down 17.6%
- MDGL Madrigal Down 8.1%
- TGTX TG Therapeutics Up 5.9%
- CORT Corcept Therapeutics Down 20.1%
- KRYS Krystal Down 11%
Show all 17
- ARWR Arrowhead Down 15.3%
- IOVA Iovance Down 35.4%
- TNGX Tango Therapeutics Down 16.4%
- SLS SELLAS Up 156.4%
- VKTX Viking Therapeutics
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
- NRIX Nurix Therapeutics Down 38.2%
- AGIO Agios Down 9.9%
- IMCR Immunocore Up 9.1%
- ORIC ORIC Pharmaceuticals Down 32%
Questions about Genmab
- How does Genmab make money?
- Mostly from royalties on antibody drugs it invented and licensed to larger companies, above all Johnson & Johnson's multiple myeloma drug Darzalex. It also sells two medicines of its own with partners: EPKINLY for lymphoma, with AbbVie, and Tivdak for cervical cancer, with Pfizer. More in the Long View →
- What happens to Genmab when Darzalex royalties fall?
- Genmab expects its Darzalex royalties, its biggest source of income, to begin to decline materially in 2029, when its US patent rights expire. It is building its own medicines to replace them, including two drugs it acquired: Rina-S and petosemtamab. More in the Long View →
- Does Genmab have debt?
- Yes, since December 2025, when it borrowed $5.5 billion in term loans and notes to help pay for Merus. The final maturities fall between 2030 and 2033, with loan instalments due earlier; the Term A loan and the revolving credit facility carry financial covenants tested each quarter. More in the Long View →
- Who are Genmab's main partners?
- Johnson & Johnson, which sells Darzalex and other drugs built on Genmab technology and pays most of Genmab's revenue; Novartis, through Kesimpta royalties; AbbVie, its partner on EPKINLY; and Pfizer, its partner on Tivdak. More in the Long View →
- What's coming up for Genmab's pipeline in the next 12 months?
- Genmab says its October Phase 3 readouts for epcoritamab, Rina-S and petosemtamab support multiple regulatory submissions and potential launches in 2027, and it expects to launch petosemtamab in 2027, subject to results and approvals. Full results are to be presented at medical meetings; no filing dates have been given. As of Nov 12, 2026 More in the Long View →